Kyverna Therapeutics
KYTX | NASDAQ
$4.76
-$0.29 (-5.74%)
At close: Nov 16, 2026, 4:00 PM ET
$4.76
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Kyverna Therapeutics Company Profile
Company profile explainedCompany Profile
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Key Executives
| Name | Position |
|---|---|
| Warner Biddle | Chief Executive Officer & Director |
| Gregory Martini | Chief Financial Officer |
| Mayo Pujols | Chief Technology Officer |
| Cara Bauer | Chief Human Resources Officer |
| Christi L. Shaw | Executive Chairperson |
| Dan Maziasz | Chief Business Officer |
| Jessica Serra | Head of Investor Relations |
| Naji Gehchan | Chief Medical & Development Officer |
| Ritesh Srivastava | Chief Legal & Compliance Officer |
| Tom Van Blarcom | Senior Vice President & Head of Research |
| Tracy Rossin | Senior Vice President of Corporate Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 19, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Sep 24, 2026 | 8-K | Current Report |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 11, 2026 | 10-Q | Quarterly Report |
| Aug 11, 2026 | 8-K | Current Report |
| Jul 29, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Jul 27, 2026 | 8-K | Current Report |
| Jul 09, 2026 | 8-K | Current Report |
| Jun 02, 2026 | 8-K | Current Report |
| May 29, 2026 | 4 | Filing |
Kyverna Therapeutics
| Country | United States |
| IPO Date | Feb 9, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 149 |
| CEO | Warner Biddle |
Contact Details
5980 Horton Street Emeryville,
California 94608 United States
Stock Details
| Ticker Symbol | KYTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001994702 |
| CUSIP Number | 501976104 |
| ISIN Number | US5019761049 |
| SIC Code | 2836 |
Add to Watchlist
Select watchlists to add or remove KYTX